(lp0
S'Madrigal Pharmaceuticals Inc. MarketWatch - Jul 25, 2016 Madrigal Pharmaceuticals Inc. NASDAQ: MDGL. GO. Set Alerts &middot; Find a Broker &middot; Join TD Ameritrade &middot; Market Index &middot; Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.'
p1
aS'Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading ... GlobeNewswire  - Jul 22, 2016 FORT WASHINGTON, Pa., July 22, 2016  -- Madrigal Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the&nbsp;...'
p2
aS"Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License ... GlobeNewswire  - Sep 19, 2016 CONSHOHOCKEN, Pa. and WATERTOWN, Mass., Sept. 19, 2016  -- Madrigal Pharmaceuticals, Inc.  and Tarveda Therapeutics, Inc. today announced an exclusive worldwide license agreement providing for the&nbsp;...With $163M Deal, Tarveda Revives Synta Pharma's Cancer Drug Work - XconomyTarveda to Develop Oncology Treatments Based on Madrigal's HSP90 Drug ... - Genetic Engineering & Biotechnology News "
p3
aS'Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL ... GlobeNewswire  - Feb 23, 2017 CONSHOHOCKEN, Pa., Feb. 23, 2017  -- Madrigal Pharmaceuticals, Inc.  today announced that the first patient has been dosed in its Phase 2 study of MGL-3196 for the treatment of heterozygous familial&nbsp;...'
p4
aS'Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL ... GlobeNewswire  - Oct 20, 2016 CONSHOHOCKEN, Pa., Oct. 20, 2016  -- Madrigal Pharmaceuticals, Inc.  today announced that the first patient has been dosed in its Phase 2 study of MGL-3196 for the treatment of non-alcoholic steatohepatitis .'
p5
aS'Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals Zacks.com - Apr 15, 2016 This all-stock transaction will lead to the formation of a new company named Madrigal Pharmaceuticals, which will focus on the development of novel small-molecule drugs addressing major unmet needs related to cardiovascular-metabolic diseases and&nbsp;...Synta Pharma and Madrigal Pharma to merge in all-stock deal - Seeking AlphaSynta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular ... - Business Wire '
p6
aS'BRIEF-Madrigal Pharmaceuticals initiates Phase 2 study of MGL-3196 in patients ... Reuters - Feb 23, 2017  By Trevor Hunnicutt NEW YORK, Feb 23 Investors are showing increasing comfort wading into the markets, lavishing cash on U.S.'
p7
aS'Synta - Madrigal Merger: Is There A Potential Value Play Here? Seeking Alpha - Aug 23, 2016 On April 13, 2016 Synta and Madrigal Pharmaceuticals  entered into an arrangement and plan of merger pursuant to which Saffron Merger Sub Inc., a wholly owned subsidiary of Synta, will merge into MDGL, with Madrigal surviving as the&nbsp;...'
p8
aS'Madrigal Pharmaceuticals Inc  Stock Technicals Hit Weakness CML News - Feb 23, 2017 This is a technical analysis stock rating for Madrigal Pharmaceuticals Inc  . The company has a two bull technical rating which indicates some weakness.'
p9
aS'Synta Pharmaceuticals Has Great Product But No Money Seeking Alpha  - Mar 18, 2015 There is tremendous support among the cancer community for ganetespib, with third-party groups sponsoring most of its advanced trials.'
p10
a.